Holen Sie sich die Stockscreener-App
0.7788
0.88%
0.0068
Handel nachbörslich:
.79
0.0112
+1.44%
Schlusskurs vom Vortag:
$0.772
Offen:
$0.768
24-Stunden-Volumen:
277.30K
Relative Volume:
0.44
Marktkapitalisierung:
$52.79M
Einnahmen:
$9.14M
Nettoeinkommen (Verlust:
$-124.31M
KGV:
-0.8135
EPS:
-0.9573
Netto-Cashflow:
$-125.43M
1W Leistung:
-2.19%
1M Leistung:
-16.26%
6M Leistung:
-16.44%
1J Leistung:
-56.97%
1-Tages-Spanne:
$0.741
$0.789
1-Wochen-Bereich:
$0.741
$0.7999
52-Wochen-Spanne:
$0.716
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.7788 | 52.39M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Lynx1 Capital discloses 13.1% position in TScan Therapeutics (TCRX) common stock - Stock Titan
Biotechnology Value Fund group (TCRX) reports 9.99% TScan ownership with large warrants - Stock Titan
Equities Analysts Set Expectations for TCRX FY2026 Earnings - marketbeat.com
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - uk.finance.yahoo.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - marketbeat.com
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - Kalkine
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - marketbeat.com
TScan Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses - scanx.trade
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Tscan Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
TScan Therapeutics, Inc. 2Q 2026: Revenue $1.05M, Net loss $30.36M, EPS $(0.23) — 10-Q Summary - TradingView
TScan Therapeutics (TCRX) narrows loss but warns on going-concern outlook and debt - Stock Titan
TScan Therapeutics reports Q2 2026: $1.1M revenue, $30.4M net loss, cash $100.2M - TradingView
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TScan Therapeutics (TCRX) narrows Q2 2026 loss and doses first patient in Phase 3 ALLOHA-2 trial - Stock Titan
TScan Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
TScan Therapeutics Inc (TCRX) Stock News Today - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Expands By 95.5% - marketbeat.com
TScan doses first patient in phase 3 AML, MDS trial By Investing.com - Investing.com Nigeria
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
TScan doses first patient in phase 3 AML, MDS trial - Investing.com
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Income Statement - TradingKey
TScan Therapeutics Inc (TCRX) Cash Flow - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.765|Chg%:-0.029 - TradingKey
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Balance Sheet - TradingKey
TScan Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.782|Chg%:-0.012 - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology - TipRanks
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from Analysts - marketbeat.com
TScan Therapeutics (TCRX) Bounces Off Support, Tests Key Resistance at $0.96Fibonacci Time Zone - dars.gov.et
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Cellares and Sonoma partner to automate cell therapy manufacturing - Yahoo Finance
TScan Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseGuidance Update - dars.gov.et
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - AOL.com
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):